Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Journal of Neurochemistry

Volumn 118, Issue 4, 2011, Pages 658-667

  Boutajangout, Allal ^a   Ingadottir, Johanna ^b   Davies, Peter ^c   Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ICELAND   (Iceland)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

behavior; immunotherapy; mice; PHF1; tangles; tau

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PHF1; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM; COGNITION; CONTROLLED STUDY; DENTATE GYRUS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOTHERAPY; LOCOMOTION; MOTOR CORTEX; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; ROTAROD TEST; TASK PERFORMANCE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ASTROCYTES; BLOTTING, WESTERN; BRAIN; BRAIN CHEMISTRY; BRAIN STEM; DATA INTERPRETATION, STATISTICAL; DENTATE GYRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOSIS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNIZATION, PASSIVE; IMMUNOHISTOCHEMISTRY; MICE; MOTOR ACTIVITY; MOTOR CORTEX; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; POSTURAL BALANCE; TAU PROTEINS; TAUOPATHIES;

MUS;

EID: 79960563632     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07337.x     Document Type: Article

References (55)

1. Asuni A. A., Boutajangout A., Scholtzova H., Knudsen E., Li Y. S., Quartermain D., Frangione B., Wisniewski T., and, Sigurdsson E. M., (2006) Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages. Eur. J. Neurosci. 24, 2530-2542. (Pubitemid 44726765)
2. Asuni A. A., Boutajangout A., Quartermain D., and, Sigurdsson E. M., (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129. (Pubitemid 47312068)
3. Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D., and, Hyman B. T., (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22, 7873-7878. (Pubitemid 35379092)
4. Bard F., Cannon C., Barbour R., et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919. (Pubitemid 30644751)
5. Bendiske J., and, Bahr B. A., (2003) Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis-An approach for slowing Alzheimer disease? J. Neuropathol. Exp. Neurol. 62, 451-463. (Pubitemid 36560187)
6. Berger Z., Ravikumar B., Menzies F. M., et al. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433-442. (Pubitemid 43159895)
7. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., and, Rosenmann H., (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472-485.
8. Boutajangout A., Leroy K., Touchet N., Authelet M., Blanchard V., Tremp G., Pradier L., and, Brion J. P., (2002) Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci. Lett. 318, 29-33. (Pubitemid 34084958)
9. Boutajangout A., Authelet M., Blanchard V., Touchet N., Tremp G., Pradier L., and, Brion J. P., (2004) Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol. Dis. 15, 47-60. (Pubitemid 38134380)
10. Boutajangout A., Ingadottir J., Davies P., and, Sigurdsson E. M., (2010a) Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy. Alzheimers & Dement. 6, S578.
11. Boutajangout A., Quartermain D., and, Sigurdsson E. M., (2010b) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 16559-16566.
12. Brion J. P., Hanger D. P., Bruce M. T., Couck A. M., Flamentdurand J., and, Anderton B. H., (1991) Tau in Alzheimer neurofibrillary tangles-N-terminal and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem. J. 273, 127-133.
13. Clavaguera F., Bolmont T., Crowther R. A., et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913.
14. Das P., Howard V., Loosbrock N., Dickson D., Murphy M. P., and, Golde T. E., (2003) Amyloid-β immunization effectively reduces amyloid deposition in FcRÎ?-/- knock-out mice. J. Neurosci. 23, 8532-8538. (Pubitemid 37158753)
15. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M., and, Holtzman D. M., (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850-8855. (Pubitemid 32678116)
16. Dodart J. C., Meziane H., Mathis C., Bales K. R., Paul S. M., and, Ungerer A., (1999) Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein. Behav. Neurosci. 113, 982-990. (Pubitemid 30130872)
17. Ferrer I., Boada R. M., Sanchez Guerra M. L., Rey M. J., and, Costa-Jussa F., (2004) Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 14, 11-20. (Pubitemid 38200585)
18. Fisher Y., Nemirovsky A., Baron R., and, Monsonego A., (2010) T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One 5, e10830.
19. Frost B., Jacks R. L., and, Diamond M. I., (2009) Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852.
20. Gilman S., Koller M., Black R. S., et al. (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. (Pubitemid 40617691)
21. Greenberg S. G., and, Davies P., (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 87, 5827-5831.
22. Greenberg S. G., Davies P., Schein J. D., and, Binder L. I., (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267, 564-569.
23. Hamano T., Gendron T. F., Causevic E., Yen S. H., Lin W. L., Isidoro C., DeTure M., and, Ko L. W., (2008) Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur. J. Neurosci. 27, 1119-1130. (Pubitemid 351432336)
24. Hock C., Konietzko U., Streffer J. R., et al. (2003) Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38, 547-554. (Pubitemid 36645030)
25. Holmes C., Boche D., Wilkinson D., et al. (2008) Long-term effects of Aβ(42) immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
26. Ikeda K., Akiyama H., Arai T., Kondo H., Haga C., Iritani S., and, Tsuchiya K., (1998) Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer's disease and control brains. Neurosci. Lett. 258, 113-116. (Pubitemid 28566187)
27. Janus C., Pearson J., McLaurin J., et al. (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982. (Pubitemid 32101644)
28. Keizer R. J., Huitema A. D., Schellens J. H., and, Beijnen J. H., (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493-507.
29. Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S., and, Ashe K. H., (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335. (Pubitemid 35386387)
30. Krishnamurthy P. K., Deng Y., Mathews P. M., and, Sigurdsson E. M., (2010) Mechanistic studies of antibody mediated clearance of tau aggregates using an ex vivo brain slice model. Alzheimers & Dement. 6, S276.
31. Lemere C. A., Spooner E. T., LaFrancois J., et al. (2003) Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. 14, 10-18. (Pubitemid 37103175)
32. Lewis J., McGowan E., Rockwood J., et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405. (Pubitemid 32983430)
33. Lim F., Hernandez F., Lucas J. J., Gomez-Ramos P., Moran M. A., and, Avila J., (2001) FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol. Cell. Neurosci. 18, 702-714. (Pubitemid 34060150)
34. Lin W. L., Lewis J., Yen S. H., Hutton M., and, Dickson D. W., (2003) Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J. Neurocytol. 32, 1091-1105. (Pubitemid 39004719)
35. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., and, Schenk D., (2005a) Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131. (Pubitemid 40082949)
36. Masliah E., Rockenstein E., Adame A., et al. (2005b) Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 46, 857-868. (Pubitemid 40805347)
37. Meeker M. L., Meeker R. B., and, Hayward J. N., (1987) Accumulation of circulating endogenous and exogenous immunoglobulins by hypothalamic magnocellular neurons. Brain Res. 423, 45-55. (Pubitemid 17157153)
38. Morgan D., Diamond D. M., Gottschall P. E., et al. (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985. (Pubitemid 32101645)
39. Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H., and, Weller R. O., (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, 448-452. (Pubitemid 36460079)
40. Nicoll J. A., Barton E., Boche D., et al. (2006) Aβ species removal after Aβ42 immunization. J. Neuropathol. Exp. Neurol. 65, 1040-1048.
41. Nixon R. A., (2007) Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120, 4081-4091.
42. Orgogozo J. M., Gilman S., Dartigues J. F., et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54. (Pubitemid 36818745)
43. Otvos L. Jr, Feiner L., Lang E., Szendrei G. I., Goedert M., and, Lee V. M., (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669-673.
44. Schenk D., (2002) Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828. (Pubitemid 135706694)
45. Schenk D., Barbour R., Dunn W., et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. (Pubitemid 29327547)
46. Schwartz M., and, Shechter R., (2010) Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev. Neurol. 6, 405-410.
47. Sigurdsson E. M., (2006) Immunotherapy for conformational diseases. Curr. Pharm. Des. 12, 2569-2585.
48. Sigurdsson E. M., (2009) Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr. Alzheimer Res. 6, 446-450.
49. Sigurdsson E. M., Lorens S. A., Hejna M. J., Dong X. W., and, Lee J. M., (1996) Local and distant histopathological effects of unilateral amyloid-β 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging 17, 893-901. (Pubitemid 27022743)
50. Sigurdsson E. M., Scholtzova H., Mehta P. D., Frangione B., and, Wisniewski T., (2001) Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447. (Pubitemid 32751074)
51. Sigurdsson E., Wisniewski T., and, Frangione B., (2002) Infectivity of amyloid diseases. Trends Mol. Med. 8, 411.
52. Sigurdsson E. M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., Goni F., Frangione B., and, Wisniewski T., (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J. Neurosci. 24, 6277-6282. (Pubitemid 38944217)
53. Solomon B., Koppel R., Frankel D., and, Hanan-Aharon E., (1997) Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA 94, 4109-4112. (Pubitemid 27180507)
54. Tampellini D., Magrane J., Takahashi R. H., Li F., Lin M. T., Almeida C. G., and, Gouras G. K., (2007) Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. J. Biol. Chem. 282, 18895-18906. (Pubitemid 47100144)
55. Wang Y., Martinez-Vicente M., Kruger U., Kaushik S., Wong E., Mandelkow E. M., Cuervo A. M., and, Mandelkow E., (2009) Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum. Mol. Genet. 18, 4153-4170.